Rodrigo Ramos
Instituto Português de Oncologia Francisco Gentil
9 Papers
3 Citations
Rodrigo Ramos is an academic researcher from Instituto Português de Oncologia Francisco Gentil. The author has contributed to research in topics: Medicine & Prostate cancer. The author has an hindex of 1, co-authored 4 publications.
Chat about Author
Papers
Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial.
Karim Fizazi,Neal D. Shore,Matthew R. Smith,Rodrigo Ramos,Robert J Jones,Günter Niegisch,Egils Vjaters,Yuan Wang,Shankar Srinivasan,Toni Sarapohja,F. Verholen +10 more
TL;DR: The OS benefit and safety of darolutamide remained consistent with that observed in the overall ARAMIS population, even in patients with high numbers of comorbidities or concomitant medications.
8
Ressecção anterior do reto vs prostatectomia radical. Existem diferenças na reabilitação sexual
TL;DR: Despite the technical differences of these surgeries, from the sexual point of view these patients benefit with a penile rehabilitation, according to a unicenter retrospective cohort study.
Intrauterine device migration into the bladder with stone formation after radiochemotherapy for cervical cancer: a case report.
TL;DR: The intrauterine contraceptive device (IUD) is one of the most frequently used contraceptive methods in the world as mentioned in this paper. It is considered a safe and effective method of contraception.
3
Efficacy and safety outcomes of darolutamide in patients with nonmetastatic castration-resistant prostate cancer with comorbidities and concomitant medications from ARAMIS.
Karim Fizazi,Neal D. Shore,Marcus R. Smith,Rodrigo Ramos,Robert Jones,Guenter Niegisch,Egils Vjaters,J.A. Ortiz,Steve Liang,Yuan Wang,Shankar Srinivasan,Toni Sarapohja,F. Verholen +12 more
TL;DR: The OS benefit and safety of DARO remained consistent with that observed in the overall ARAMIS population, even in patients with a high number of comorbidities or concomitant medications.
2